Form D · Biotechnology

CYTOVALE INC.

San Francisco, CA · CIK 0001725779

Offering snapshot reported Jan 3, 2022 · SEC filing

Reported sold: $16.4M
Investors reported: 23
Minimum accepted: $0
First sale: Dec 18, 2020

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$8,010,000 → $16,435,000
Reported investors17 → 23

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 3, 2022	Amendment	$16,435,000	$8,425,000vs Jan 4, 2021	23	SEC filing
Jan 4, 2021	Initial	$8,010,000	No comparison	17	SEC filing
Oct 30, 2019	Initial	$7,433,484	No comparison	15	SEC filing
Dec 26, 2017	Initial	$7,249,989	No comparison	7	SEC filing

Offering details

Securities: Debt
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-385088

Source: Form D, filed Jan 3, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
William Blackledge	Executive
Dino Di Carlo	Director, Promoter
Lindy Fishburne	Director
Jack Fuchs	Director, Promoter
Jordanna Polis Schutz	Director
Ajay Shah	Director, Executive, Promoter
Henry Tse	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

150 Executive Park Blvd, Suite 4100
San Francisco, CA, 94134